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ABSTRACT
Experiments conducted in non-human primates have recently provided new evidence supporting a
longstanding concern that exposure to general anesthesia during late intrauterine life or early
childhood can cause lasting cognitive deficits through harmful effects on brain development. The
mammalian target of rapamycin (mTOR) signaling system plays a key role in both normal brain
development and in a wide range of developmental disorders that are characterized by cognitive
deficits. Intriguingly, our recently published work shows that anesthetics can chronically alter mTOR
signaling in the hippocampal dentate gyrus and that normalization of mTOR signaling can prevent
anesthesia-induced perturbation of structure and function. In this addendum, we briefly discuss the






The United States Food and Drug Administration has
recently required that 12 commonly used anesthetic
and sedative agents with mechanisms of action on
NMDA and GABA receptors carry labels warning that
repeated or lengthy exposure to these drugs between
the third trimester and the first three years of life may
result in adverse consequences for brain development
[1]. These safety concerns are based on a combination
of findings from human subjects research and animal
model studies including rodents and primates. While
the only prospective studies of pediatric patients con-
ducted to date indicate that a short, single exposure to
general anesthesia does not result in cognitive deficits
[2,3], several large retrospective studies have found an
association between anesthesia/surgery exposure in
young children and worsened cognitive function at later
ages [4–6]. The interpretation of the medical relevance
of these studies is complex at best, and it may never be
possible to design an ethical clinical study that answers
fundamental questions about what kind of harm may
come from anesthetic exposure. Multiple independent
investigations have concluded that early postnatal
exposure to general anesthesia in rodents can cause
lasting deficits on behavioral tests on learning and
memory e.g. [7–10]. It should be noted that some
studies in rodents have found no effects of anesthetics
on cognitive function [11] and others have even found
neuroprotective effects [12,13]. There is considerable
variability between models of early developmental anes-
thesia which complicates the interpretation of the
rodent literature, and any roent model is potentially
complicated by the need for high doses to cause general
anesthesia, the difficulty in selecting an appropriate
control condition, and the possibility of physiologic
perturbation such as hypoxia, hypercarbia, hypoten-
sion, and hypothermia. The most compelling evidence
in support of developmental anesthetic neurotoxicity
comes from a recent study in non-human primates by
Baxter and co-workers that showed clear deficits in
visual recognition memory resulting from clinically rel-
evant exposures to general anesthesia. These data are
free from the confounds of surgery and co-morbid dis-
ease which complicate the interpretation of clinical
investigations and the model for anesthesia exposure
much more closely resembles human pediatric general
anesthesia than the published rodent models [14]. The
mechanisms by which general anesthetics might disrupt
brain development have yet to be clearly defined. Early
work on this topic identified molecular evidence of
upregulation of pro-apoptotic pathways by general
anesthetic drugs in the developing brain [15–17], but
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more recent studies have cast doubt on whether cell
death is the principal mechanism of damage in
anesthetic neurotoxicity [18–20]. Thus, it is of interest
to consider other potential mechanisms of injury, par-
ticularly those which relate developmental anesthetic
neurotoxicity to better-studied disorders of brain devel-
opment. In this addendum to our recently published
work, Kang et al 2017, we briefly discuss mTOR dysre-
gulation in neurodevelopmental disease and we place
our findings in the context of two other recent studies
related to anesthetic neurotoxicity.
2. The mTOR pathway and neurodevelopmental
disease
The mTOR protein is a highly conserved protein
kinase which is the key participant in two protein
complexes, mTOR complex 1 and 2 that play a criti-
cal role in growth, metabolism, and homeostasis in
almost every eukaryotic cell type. mTOR complexes
regulate the integrated response of multiple signaling
pathways to a wide array of intracellular sensing cues
and extracellular signals [21]. In the developing ner-
vous system, mTOR plays a key role in a wide variety
of normal processes, including neural stem cell regu-
lation, cellular migration, and dendrite, axon and
synapse development [22]. Thus, it is unsurprising
that perturbations in mTOR signaling are potentially
pathological, although given the complexity of the
pathway it can be difficult to determine whether
changes in mTOR signaling are the cause of pathol-
ogy or a consequence of it. One of the best-studied
examples of the role of aberrant mTOR activity in
the pathology of neurodevelopmental disease is in
tuberous sclerosis, a multisystem genetic disorder that
can include intellectual disability, developmental
delay, and autism spectrum disorder (ASD). Tuberous
sclerosis results from mutations in TSC1 and TSC2,
which are direct negative regulators of the mTORC1
complex [23,24]. Transgenic mouse models of tuber-
ous sclerosis such as Tsc2+/¡ and Tsc1+/¡ exhibit
increased activity in the mTOR pathway, which is
accompanied by deficits in long-term potentiation
and spatial learning, which can be reversed by
chronic treatment with a rapamycin, a mTOR path-
way inhibitor [25]. Another well-characterized exam-
ple is Fragile X syndrome, the most common
developmental cause of mental retardation and a
common cause of ASD, which results from the tran-
scriptional silencing of the FMR1 gene. Elevated
mTOR signaling is observed in the Fmr1-/- mouse
model of Fragile X Syndrome e.g.[26], however, the
connection between Fmr1 and mTOR has not been
fully elucidated. While later treatment with rapamycin
does not necessarily reverse pathology associated with
the Fmr1 knockout [26], a double knockout that
also deletes S6 Kinase does not show the synaptic
and behavioral deficits associated with Fmr1-/- alone
[27]. A role for mTOR has also been postulated for a
variety of neuropsychiatric disorders, including other
causes of ASD, schizophrenia, drug addiction and
depression [28]. While changes in the mTOR pathway
in these disorders are not simple or uniform, the
trend is generally that inappropriately increased activ-
ity is associated with pathology.
3. mTOR as a target in developmental
anesthetic neurotoxicity
Because the mTOR pathway is involved in many processes
brain development, any pharmacologic action on this sig-
naling pathway has the potential to cause a pathologic
state. The first report that a widely used general anesthetic
acts on the mTOR pathway came from a study conducted
in the human umbilical vein endothelial cell line, which
found that isoflurane exposure increased levels of phos-
pho-Akt, phospho-mTOR, and phospho-GSK3B and that
effects of isoflurane on hypoxia-inducible factor 1 can be
blocked with rapamycin [29]. Two manuscripts published
this past year have provided evidence that increased activ-
ity in the mTOR pathway may contribute to the pheno-
type of developmental anesthetic neurotoxicity. Na and
co-workers found that rapamycin treatment prevented the
loss of chemotaxis that results from developmental expo-
sure of C. elegans to isoflurane. Based on this data and the
results of a forward genetics screen that identified endo-
plasmic reticulum stress pathways as a target in anes-
thetic-induced neurotoxicity, that isoflurane acts on
mitochondria to create reactive oxygen species that in turn
activate the mTOR pathway [30]. In our recently pub-
lished manuscript, we described a study in a mouse model
of developmental anesthetic neurotoxicity which revealed
that anesthetic effects on mTOR signaling profoundly dis-
rupted development of newborn dentate gyrus granule
cells in the hippocampus. Isoflurane exposure was found
to cause a lasting increase in phospho-S6 (pS6) levels that
was accompanied by a reduction in mushroom spines.
Both the spine loss and behavioral deficits in learning
induced by anesthetic exposure could be reversed by treat-
ment with rapamycin. We concluded that isoflurane
caused a chronic upregulation of mTOR that disrupted
the developmental program in this vulnerable cohort of
neurons, which are critical for learning functions [10].
Of note, several previous reports suggest that anes-
thetics may act to suppress mTOR activity in the hippo-
campus in rodent models of anesthetic neurotoxicity, a
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finding that may or may not be at odds with ours given
differences in study design and in what was measured.
For example, work in both primary cultured hippocam-
pal neurons and in the intact hippocampus, Li et al.
found that isoflurane exposure during development
acutely reduced phospho-S6 via inhibition of the Insu-
lin-like growth factor 1(IGF-1)/ Phosphoinositide 3-
kinase (PI3K)/ Protein Kinase B (Akt) pathway [31].
Furthermore, they found that that treatment with IGF-
1 on the day of exposure and for two days afterward
restored performance on behavioral tests of learning
that were impaired with isoflurane exposure in their
model. There are, of course, differences in the exposure
paradigm between this report and ours, but perhaps the
most striking difference is that we measured pS6 levels
at 12 and 42 days after the exposure, rather than imme-
diately after the exposure. Liu et al., working in an aged
rodent model rather than during development, found
that sevoflurane exposure resulted in a decrease in
phospho-mTOR levels in the hippocampus that per-
sisted for 7 days after exposure [32]. However, no later
time points were measured, and intriguingly they found
that sevoflurane exposure did not result in any change
in pS6 levels between 1 and 7 days of exposure. The
model in this study differs very substantially from our
own in terms of the aged versus developing hippocam-
pus, but certainly these findings do not support a uni-
versal or uniform effect of anesthetics on the mTOR
pathway.
It is not year clear how to reconcile the currently pub-
lished studies currently on the effects of anesthetics on
the mTOR pathway. Some of the difficulty results from a
broader problem in the field of developmental anesthetic
neurotoxicity where there is currently no standard model
of anesthetic exposure nor any agreed upon standard for
measurable outcomes and time points at which these
outcomes are considered relevant. Nevertheless, there is
now preliminary evidence suggesting that anesthetics
can have unintended and harmful effects on the mTOR
pathway, and given the importance of this pathway for
brain development, we feel that this new avenue of inves-
tigation deserves further consideration.
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